The Claim
Combination therapy with photodynamic therapy and anti-VEGF agents maintains a subretinal hemorrhage rate of ≤2.0% in treatment-naïve patients with polypoidal choroidal vasculopathy, with no significant difference in rate compared to monotherapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with polypoidal choroidal vasculopathy who have not received prior treatment, combining photodynamic therapy with anti-VEGF drugs results in a subretinal hemorrhage rate of 2% or less, which is not higher than the rate seen with a single therapy.
See the scientific wording
Combination therapy with photodynamic therapy and anti-VEGF agents maintains a low rate of subretinal hemorrhage (≤2.0%) in treatment-naïve patients with polypoidal choroidal vasculopathy, comparable to monotherapy, indicating no significant increase in ocular safety risk.
The abnormal blood vessels in the eye become less fragile and less likely to break when treated, so bleeding under the retina stays rare no matter which treatment is used.
What the research says
1 studyAdding PDT to eye injections for this eye condition doesn’t make bleeding in the eye more likely — it’s just as safe as using the injections alone.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.